Skip to main content
PMC home page
Japanese Journal of Cancer Research : Gann logoLink to Japanese Journal of Cancer Research : Gann
. 2000 Dec;91(12):1326–1332. doi: 10.1111/j.1349-7006.2000.tb00921.x

Cytotoxicity of cis‐[((1R,2R)‐1,2‐Cyclohexanediamine‐N,N')bis(myristato)]‐platinum (II) Suspended in Lipiodol in a Newly Established Cisplatinresistant Rat Hepatoma Cell Line

Shuichi Kishimoto 1,✉, Kenji Miyazawa 1, Yoko Terakawa 1, Hiromi Ashikari 1, Aya Ohtani 1, Shoji Fukushima 1, Yoshikazu Takeuchi 1
PMCID: PMC5926295  PMID: 11123433

Abstract

The cytotoxic activity of cis‐[((1R,2R)‐1,2‐cyclohexanediamine‐N,N')bis(myristato)]platinum (II) (SM‐11355) was evaluated in a cisplatin (CDDP)‐resistant tumor cell line, and compared with that of CDDP. H4‐II‐E/CDDP with acquired resistance to CDDP was established by continuous exposure of a rat hepatic tumor line, H4‐II‐E, to increasing concentrations of CDDP over 12 months. Compared with the parental cell line, this cell line exhibited an 8.8‐fold increase in resistance to CDDP and was not cross‐resistant to 1,2‐diaminocyclohexane platinum (II) dichloride (DPC). There were no differences in sensitivity to six non‐platinum antitumor drugs between H4‐II‐E and H4‐II‐E/CDDP, which suggests that H4‐II‐E/CDDP is not multidrug‐resistant. Intracellular platinum accumulation and the formation of a platinum‐DNA adduct following CDDP exposure were significantly reduced in H4‐II‐E/CDDP compared to the parental cell line. The acquired CDDP resistance in H4‐II‐E/CDDP appeared to be predominantly due to reduced CDDP uptake. H4‐II‐E/CDDP was also resistant to CDDP suspended in Lipiodol (CDDP/Lipiodol), but was not crossresistant to SM‐11355 suspended in Lipiodol (SM‐11355/Lipiodol). Also, there were no differences in intracellular platinum accumulation or the formation of platinum‐DNA adducts after SM‐11355/Lipiodol exposure between H4‐II‐E and H4‐II‐E/CDDP. These results suggest that acquired CDDP resistance in H4‐II‐E/CDDP does not influence the cytotoxic activity of SM‐11355/Lipiodol.

Keywords: Lipiodol, Cisplatin, Hepatocellular carcinoma, Sustained release, Resistance

Full Text

The Full Text of this article is available as a PDF (81.1 KB).

REFERENCES

  • 1. ) Gottesman , M. M. , Pastan , I. and Ambudkar , S. V.P‐Glycoprotein and multidrug resistance . Curr. Opin. Genet. Dev. , 6 , 610 – 617 ( 1996. ). [DOI] [PubMed] [Google Scholar]
  • 2. ) Loehrer , P. J. and Einhorn , L. H.Drugs five years later‐Cisplatin . Ann. Intern. Med. , 100 , 704 – 713 ( 1984. ). [DOI] [PubMed] [Google Scholar]
  • 3. ) Andrews , P. A. and Howell , S. B.Cellular pharmacology of cisplatin: perspectives on mechanisms of acquired resistance . Cancer Cells , 2 , 35 – 43 ( 1990. ). [PubMed] [Google Scholar]
  • 4. ) Kelley , S. L. and Rozencweig , M.Resistance to platinum compounds: mechanisms and beyond . Eur. J. Cancer Clin. Oncol. , 25 , 1135 – 1140 ( 1989. ). [DOI] [PubMed] [Google Scholar]
  • 5. ) Perez , R. P. , Hamilton , T. C. and Ozols , R. F.Resistance to alkylating agents and cisplatin: insights from ovarian carcinoma model systems . Pharmacol. Ther. , 48 , 19 – 27 ( 1990. ). [DOI] [PubMed] [Google Scholar]
  • 6. ) Fink , D. , Nebel , S. , Aebi , S. , Zheng , H. , Cenni , B. , Nehme , A. , Christen , R. D. and Howell , S. B.The role of DNA mismatch repair in platinum drug resistance . Cancer Res. , 56 , 4881 – 4886 ( 1996. ). [PubMed] [Google Scholar]
  • 7. ) Johnson , S. W. , Laub , P. B. , Beesley , J. S. , Ozols , R. F. and Hamilton , T. C.Increased platinum‐DNA damage tolerance is associated with cisplatin resistance and cross‐resistance to various chemotherapeutic agents in unrelated human ovarian cancer cell lines . Cancer Res. , 57 , 850 – 856 ( 1997. ). [PubMed] [Google Scholar]
  • 8. ) Timmer‐Bosscha , H. , Mulder , N. H. and de Vries , E. G.Modulation of cis‐diamminedichloroplatinum(II) resistance: a review . Br. J. Cancer , 66 , 227 – 238 ( 1992. ). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9. ) Christian , M. C.The current status of new platinum analogs . Semin. Oncol. , 19 , 720 – 733 ( 1992. ). [PubMed] [Google Scholar]
  • 10. ) Iwai , K. , Maeda , H. and Konno , T.Use of oily contrast medium for selective drug targeting to tumor: enhanced therapeutic effect and X‐ray image . Cancer Res. , 44 , 2115 – 2121 ( 1984. ). [PubMed] [Google Scholar]
  • 11. ) Konno , T.Targeting cancer chemotherapeutic agents by use of lipiodol contrast medium . Cancer , 66 , 1897 – 1903 ( 1990. ). [DOI] [PubMed] [Google Scholar]
  • 12. ) Konno , T.Targeting chemotherapy for hepatoma: arterial administration of anticancer drugs dissolved in Lipiodol . Eur. J. Cancer , 28 , 403 – 409 ( 1992. ). [DOI] [PubMed] [Google Scholar]
  • 13. ) Horiguchi , Y. , Itoh , M. , Takagawa , H. , Imai , H. , Kamei , A. , Sekoguchi , B. and Nagamura , Y.Assessment of chemoembolization therapy for primary liver cancer using a stabilized adriamycin‐lipiodol suspension . Cancer Chemother. Pharmacol. , 31 , S60 – S64 ( 1992. ). [DOI] [PubMed] [Google Scholar]
  • 14. ) Ikeda , K. , Inoue , H. , Yano , T. , Kobayashi , H. and Nakajo , M.Comparison of the anticancer effect of ADMOS alone and ADMOS with CDDP in the treatment of hepatocellular carcinoma by intra‐arterial injection . Cancer Chemother. Pharmacol. , 31 , S65 – S68 ( 1992. ). [DOI] [PubMed] [Google Scholar]
  • 15. ) Shibata , J. , Kimura , S. , Chikazawa , H. , Miyase , S. , Sakai , M. , Morishita , T. , Fujiyama , S. , Sato , T. , Fukushima , S. , Kishimoto , S. and Nakano , M.Intra‐hepatic artery infusional chemotherapy with cisplatin suspension in lipiodol (LPS) of hepatocellular carcinoma (II)—a clinical study . J. Jpn. Soc. Cancer Ther. , 23 , 2750 – 2759 ( 1988. ). [PubMed] [Google Scholar]
  • 16. ) Shibata , J. , Fujiyama , S. , Sato , T. , Kishimoto , S. , Fukushima , S. and Nakano , M.Hepatic arterial injection chemotherapy with cisplatin suspended in an oily lymphographic agent for hepatocellular carcinoma . Cancer , 64 , 1586 – 1594 ( 1989. ). [DOI] [PubMed] [Google Scholar]
  • 17. ) Maeda , M. , Uchida , N. A. and Sasaki , T.Liposoluble platinum(II) complexes with antitumor activity . Jpn. J. Cancer Res. (Gann) , 77 , 523 – 525 ( 1986. ). [PubMed] [Google Scholar]
  • 18. ) Kishimoto , S. , Fukui , M. , Fukushima , S. and Nakano , M.Application of a lipophilic platinum derivative contained in an oily lymphographic agent to intra‐hepatic arterial chemotherapy . Reg. Cancer Treat. , 1–2 , 25 – 29 ( 1992. ). [Google Scholar]
  • 19. ) Kishimoto , S. , Noguchi , T. , Yamaoka , T. , Fukushima , S. and Takeuchi , Y.Antitumor effects of a novel lipophilic platinum complex (SM‐11355) against a slowly‐growing rat hepatic tumor after intra‐hepatic arterial administration . Biol. Pharm. Bull. , 23 , 344 – 348 ( 2000. ). [DOI] [PubMed] [Google Scholar]
  • 20. ) Kishimoto , S. , Noguchi , T. , Yamaoka , T. , Fukushima , S. and Takeuchi , Y.In vitro cytotoxicity of cis‐[((1R,2R)‐1,2‐cyclohexanediamine‐N, N') bis (myristato)] platinum (II) suspended in Lipiodol in rat hepatoma AH‐109A cells and human tumor cell lines . Biol. Pharm. Bull. , 23 , 487 – 491 ( 2000. ). [DOI] [PubMed] [Google Scholar]
  • 21. ) Kishimoto , S. , Noguchi , T. , Yamaoka , T. , Fukushima , S. and Takeuchi , Y.In vitro release of SM‐11355, cis‐[((1R,2R)‐1,2‐cyclohexanediamine‐N, N') bis (myristato)] platinum (II) suspended in Lipiodol . Biol. Pharm. Bull. , 23 , 637 – 640 ( 2000. ). [DOI] [PubMed] [Google Scholar]
  • 22. ) Kishimoto , S. , Miyazawa , K. , Fukushima , S. and Takeuchi , Y.In vitro antitumor activity, intracellular accumulation, and DNA adduct formation of cis‐[((1R,2R)‐1,2‐cyclohexanediamine‐N, N') bis (myristato)] platinum (II) suspended in Lipiodol . Jpn. J. Cancer Res. , 91 , 99 – 104 ( 2000. ). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23. ) Kraker , A. J. and Moore , C. W.Accumulation of cis‐diamminedichloroplatinum (II) and platinum analogues by platinum‐resistant murine leukemia cells in vitro . Cancer Res. , 48 , 9 – 13 ( 1988. ). [PubMed] [Google Scholar]
  • 24. ) Gibbons , G. R. , Page , J. D. , Mauldin , S. K. , Husain , I. and Chaney , S. G.Role of carrier ligand in platinum resistance in L1210 cells . Cancer Res. , 50 , 6497 – 6501 ( 1990. ). [PubMed] [Google Scholar]
  • 25. ) Kido , Y. , Khokhar , A. R. , al‐Baker , S. and Siddik , Z. H.Modulation of cytotoxicity and cellular pharmacology of 1, 2‐diaminocyclohexane platinum (IV) complexes mediated by axial and equatorial ligands . Cancer Res. , 53 , 4567 – 4572 ( 1993. ). [PubMed] [Google Scholar]
  • 26. ) Ishiyama , M. , Shiga , M. , Sasamoto , K. , Mizoguchi , M. and He , P. G.A new sulfonated tetrazolium salt that produces a highly water‐soluble formazan dye . Chem. Pharm. Bull. , 41 , 1118 – 1122 ( 1993. ). [Google Scholar]
  • 27. ) Loe , D. W. , Deeley , R. G. and Cole , S. P.Biology of the multidrug resistance‐associated protein, MRP . Eur. J. Cancer , 32A , 945 – 957 ( 1996. ). [DOI] [PubMed] [Google Scholar]
  • 28. ) Lautier , D. , Canitrot , Y. , Deeley , R. G. and Cole , S. P.Multidrug resistance mediated by the multidrug resistance protein (MRP) gene . Biochem. Pharmacol. , 52 , 967 – 977 ( 1996. ). [DOI] [PubMed] [Google Scholar]
  • 29. ) Siddik , Z. H. , Mims , B. , Lozano , G. and Thai , G.Independent pathways of p53 induction by cisplatin and X‐rays in a cisplatin‐resistant ovarian tumor cell line . Cancer Res. , 58 , 698 – 703 ( 1998. ). [PubMed] [Google Scholar]
  • 30. ) Perez , R. P.Cellular and molecular determinants of cisplatin resistance . Eur. J. Cancer , 34 , 1535 – 1542 ( 1998. ). [DOI] [PubMed] [Google Scholar]

Articles from Japanese Journal of Cancer Research : Gann are provided here courtesy of Wiley

RESOURCES